Oncology Tube Conducts Interviews on NRG Oncology Research Presented During the 2022 ASCO Annual Meeting: NRG-HN002 and NRG-GI008

July 27 2022

Sue Yom, MD from UCSF, gave an oral presentation about the translational analysis of blood specimens for NRG-HN002, a study of (chemo)radiation treatment for 306 patients with stage I HPV+ oropharyngeal cancer. Click here to listen to the interview.

NRG-GI008 (CIRCULATE-US)Arvind Desari, MD from MD Anderson Cancer Center, led a Trials in Progress poster discussion about NRG-GI008. This study is designed to determine whether chemotherapy is needed and if so, what kind to recommend to patients based on the presence or absence of ctDNA after surgery for colon cancer. Click here to listen to the interview.

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.